Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320788 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT00320788 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 159 participants.
The verdict
NCT00320788, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD. The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.
Interventions
- BIOLOGICAL aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320788
The ClinicalTrials.gov registry entry for NCT00320788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aflibercept injection (VEGF Trap-Eye, BAY86-5321) is the first listed.
NCT00320788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320788 about?
NCT00320788 is a clinical study titled "Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)". This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD. The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to A...
What is the current status of trial NCT00320788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2006-04. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00320788?
The interventions under investigation include: aflibercept injection (VEGF Trap-Eye, BAY86-5321) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00320788?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.